340 related articles for article (PubMed ID: 15665273)
21. Oncogenic BARD1 isoforms expressed in gynecological cancers.
Li L; Ryser S; Dizin E; Pils D; Krainer M; Jefford CE; Bertoni F; Zeillinger R; Irminger-Finger I
Cancer Res; 2007 Dec; 67(24):11876-85. PubMed ID: 18089818
[TBL] [Abstract][Full Text] [Related]
22. BARD1: an independent predictor of survival in non-small cell lung cancer.
Zhang YQ; Bianco A; Malkinson AM; Leoni VP; Frau G; De Rosa N; André PA; Versace R; Boulvain M; Laurent GJ; Atzori L; Irminger-Finger I
Int J Cancer; 2012 Jul; 131(1):83-94. PubMed ID: 21815143
[TBL] [Abstract][Full Text] [Related]
23. BRCA1/BARD1 complex interacts with steroidogenic factor 1--A potential mechanism for regulation of aromatase expression by BRCA1.
Lu Y; Kang T; Hu Y
J Steroid Biochem Mol Biol; 2011 Jan; 123(1-2):71-8. PubMed ID: 21087664
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site.
Ruffner H; Jiang W; Craig AG; Hunter T; Verma IM
Mol Cell Biol; 1999 Jul; 19(7):4843-54. PubMed ID: 10373534
[TBL] [Abstract][Full Text] [Related]
25. Triggering ubiquitination of a CDK inhibitor at origins of DNA replication.
Furstenthal L; Swanson C; Kaiser BK; Eldridge AG; Jackson PK
Nat Cell Biol; 2001 Aug; 3(8):715-22. PubMed ID: 11483956
[TBL] [Abstract][Full Text] [Related]
26. BRCA1 : BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair.
Morris JR; Solomon E
Hum Mol Genet; 2004 Apr; 13(8):807-17. PubMed ID: 14976165
[TBL] [Abstract][Full Text] [Related]
27. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis.
Wu JY; Vlastos AT; Pelte MF; Caligo MA; Bianco A; Krause KH; Laurent GJ; Irminger-Finger I
Int J Cancer; 2006 Mar; 118(5):1215-26. PubMed ID: 16152612
[TBL] [Abstract][Full Text] [Related]
28. mRNA Processing Factor CstF-50 and Ubiquitin Escort Factor p97 Are BRCA1/BARD1 Cofactors Involved in Chromatin Remodeling during the DNA Damage Response.
Fonseca D; Baquero J; Murphy MR; Aruggoda G; Varriano S; Sapienza C; Mashadova O; Rahman S; Kleiman FE
Mol Cell Biol; 2018 Feb; 38(4):. PubMed ID: 29180510
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation.
Hu Q; Botuyan MV; Zhao D; Cui G; Mer E; Mer G
Nature; 2021 Aug; 596(7872):438-443. PubMed ID: 34321665
[TBL] [Abstract][Full Text] [Related]
30. Inducible expression of a degradation-resistant form of p27Kip1 causes growth arrest and apoptosis in breast cancer cells.
Zhang Q; Tian L; Mansouri A; Korapati AL; Johnson TJ; Claret FX
FEBS Lett; 2005 Jul; 579(18):3932-40. PubMed ID: 15996662
[TBL] [Abstract][Full Text] [Related]
31. Human BRCA1-BARD1 ubiquitin ligase activity counteracts chromatin barriers to DNA resection.
Densham RM; Garvin AJ; Stone HR; Strachan J; Baldock RA; Daza-Martin M; Fletcher A; Blair-Reid S; Beesley J; Johal B; Pearl LH; Neely R; Keep NH; Watts FZ; Morris JR
Nat Struct Mol Biol; 2016 Jul; 23(7):647-55. PubMed ID: 27239795
[TBL] [Abstract][Full Text] [Related]
32. Nuclear targeting and cell cycle regulatory function of human BARD1.
Schüchner S; Tembe V; Rodriguez JA; Henderson BR
J Biol Chem; 2005 Mar; 280(10):8855-61. PubMed ID: 15632137
[TBL] [Abstract][Full Text] [Related]
33. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase.
Eakin CM; Maccoss MJ; Finney GL; Klevit RE
Proc Natl Acad Sci U S A; 2007 Apr; 104(14):5794-9. PubMed ID: 17392432
[TBL] [Abstract][Full Text] [Related]
34. The basal-like mammary carcinomas induced by Brca1 or Bard1 inactivation implicate the BRCA1/BARD1 heterodimer in tumor suppression.
Shakya R; Szabolcs M; McCarthy E; Ospina E; Basso K; Nandula S; Murty V; Baer R; Ludwig T
Proc Natl Acad Sci U S A; 2008 May; 105(19):7040-5. PubMed ID: 18443292
[TBL] [Abstract][Full Text] [Related]
35. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein.
Xia Y; Pao GM; Chen HW; Verma IM; Hunter T
J Biol Chem; 2003 Feb; 278(7):5255-63. PubMed ID: 12431996
[TBL] [Abstract][Full Text] [Related]
36. ING5 is phosphorylated by CDK2 and controls cell proliferation independently of p53.
Linzen U; Lilischkis R; Pandithage R; Schilling B; Ullius A; Lüscher-Firzlaff J; Kremmer E; Lüscher B; Vervoorts J
PLoS One; 2015; 10(4):e0123736. PubMed ID: 25860957
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues.
Lombardi G; Falaschi E; Di Cristofano C; Naccarato AG; Sensi E; Aretini P; Roncella M; Bevilacqua G; Caligo MA
Genes Chromosomes Cancer; 2007 Sep; 46(9):791-5. PubMed ID: 17497650
[TBL] [Abstract][Full Text] [Related]
38. Noncatalytic requirement for cyclin A-cdk2 in p27 turnover.
Zhu XH; Nguyen H; Halicka HD; Traganos F; Koff A
Mol Cell Biol; 2004 Jul; 24(13):6058-66. PubMed ID: 15199159
[TBL] [Abstract][Full Text] [Related]
39. Tuning BRCA1 and BARD1 activity to investigate RING ubiquitin ligase mechanisms.
Stewart MD; Duncan ED; Coronado E; DaRosa PA; Pruneda JN; Brzovic PS; Klevit RE
Protein Sci; 2017 Mar; 26(3):475-483. PubMed ID: 27977889
[TBL] [Abstract][Full Text] [Related]
40. Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.
Zhu Y; Liu Y; Zhang C; Chu J; Wu Y; Li Y; Liu J; Li Q; Li S; Shi Q; Jin L; Zhao J; Yin D; Efroni S; Su F; Yao H; Song E; Liu Q
Nat Commun; 2018 Apr; 9(1):1595. PubMed ID: 29686231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
